In the Media

September 13, 2021

Journalist Vivienne Parry Interviews InMed CEO, Eric A. Adams and BayMedica Co-founder, Shane Johnson, to Talk About their Shared Vision for the Combined Company

On September 13th, journalist Vivienne Parry interviewed InMed Pharmaceuticals’ President and CEO, Eric A. Adams, and BayMedica’s co-founder, Shane Johnson. In their first interview together, Eric and Shane talked about the acquisition and their shared vision of the combined company.

Source: Edison TV

Share this post

Latest Articles

Webinar Replay: Alzheimer’s Outlook – Neuroinflammation, the Next Step

Fierce Biotech Webinar “Alzheimer’s Outlook – Neuroinflammation, the Next Step” is now available on demand. InMed’s Senior VP, Preclinical Research and Development, Dr. Eric Hsu,

December 11, 2024

Study on Anti-Inflammation by Modulation of Endocannabinoid System

A company-sponsored peer-reviewed scientific study entitled “Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes” has been published in the international journal Biofactors.

December 10, 2024

Gene Online Article: InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment

In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s

September 4, 2024